Iovance Biotherapeutics Inc (STU:2LB)
€ 8.906 -0.43 (-4.61%) Market Cap: 2.69 Bil Enterprise Value: 2.39 Bil PE Ratio: 0 PB Ratio: 3.79 GF Score: 38/100

Q3 2021 Iovance Biotherapeutics Inc Earnings Call Transcript

Nov 04, 2021 / 08:30PM GMT
Release Date Price: €21.5 (+1.80%)
Operator

Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-date 2021 Financial Results. My name is Andrew, and I'll be your operator for today's call. (Operator Instructions) Please note that today's conference is being recorded.

I will now turn the call over to Sara Pellegrino, Vice President, Investor and Public Relations at Iovance. Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Fred Vogt, our Interim President and Chief Executive Officer; Igor Bilinsky, our Chief Operating Officer; Jim Ziegler, our Senior Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. Dr. Madan Jagasia our Senior Vice President, Medical Affairs; and Laurel Todd, Vice President of Policy are also on the call to participate in the Q&A session.

This afternoon, we issued a press release that can be found on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot